David Killock

1 week ago | nature.com | David Killock

Trastuzumab plus platinum–fluoropyrimidine chemotherapy has been the backbone of frontline therapy for advanced-stage HER2-positive gastroesophageal adenocarcinoma (HER2+ GEA) since 2010 on the basis of results from the landmark phase III ToGA trial. Now, data from a phase II trial indicate that zanidatamab, a biparatopic antibody targeting two distinct epitopes of HER2, might improve outcomes in this setting.

1 week ago | nature.com | David Killock

Perioperative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improves overall survival (OS) in patients with resectable gastric or gastroesophageal junction adenocarcinoma (G/GEJA), yet most will have recurrence and ultimately die of the disease. Now, new data from the phase III MATTERHORN trial indicate that adding the anti-PD-L1 antibody durvalumab further improves outcomes in this setting.

1 week ago | nature.com | David Killock

In 2024, the bispecific DLL3 × CD3 T cell engager tarlatamab was granted FDA accelerated approval for previously treated extensive stage small cell lung cancer (SCLC) on the basis of data from the single-arm phase II DeLLphi-301 trial. Now, results from the confirmatory phase III DeLLphi-304 trial demonstrate that tarlatamab improves outcomes compared with the current second-line standard of care.

1 month ago | nature.com | David Killock

The covalent KRAS-G12C inhibitors adagrasib and sotorasib are approved for patients with previously treated KRASG12C-mutant non-small-cell lung cancer (NSCLC) or colorectal cancer (CRC); however, the efficacy of these agents is limited, in large part, by suboptimal target engagement.

2 months ago | nature.com | David Killock

Patients with progression of metastatic triple-negative breast cancer (mTNBC) following first-line treatment have a dismal prognosis. The TROP2-directed antibody–drug conjugate (ADC) sacituzumab govitecan improves outcomes in this setting. New data from the phase III OptiTROP-Breast01 trial support sacituzumab tirumotecan (sac-TMT), a different anti-TROP2 ADC with a linker designed for improved bioactivity, as another treatment option for such patients.